Published in J Clin Microbiol on November 01, 2004
Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev (2007) 15.82
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother (2007) 5.36
Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol (2005) 2.89
First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother (2005) 2.29
Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med (2012) 2.09
Complete genome sequence of the multiresistant taxonomic outlier Pseudomonas aeruginosa PA7. PLoS One (2010) 2.03
Establishing clonal relationships between VIM-1-like metallo-beta-lactamase-producing Pseudomonas aeruginosa strains from four European countries by multilocus sequence typing. J Clin Microbiol (2006) 1.72
Pseudomonas aeruginosa population structure revisited. PLoS One (2009) 1.68
Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One (2011) 1.48
Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem (2014) 1.41
First detection of metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from Colombia. Antimicrob Agents Chemother (2006) 1.15
VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain. Emerg Infect Dis (2012) 1.09
A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (2014) 1.08
Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother (2006) 1.08
Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study. Crit Care (2006) 1.03
Molecular epidemiology of VIM-4 metallo-beta-lactamase-producing Pseudomonas sp. isolates in Hungary. Antimicrob Agents Chemother (2006) 1.00
Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa. Infect Chemother (2015) 0.86
Four Year Trend of Carbapenem-Resistance in Newly Opened ICUs of a University-Affiliated Hospital of South Korea. Tuberc Respir Dis (Seoul) (2012) 0.86
Novel VIM metallo-beta-lactamase variant, VIM-24, from a Klebsiella pneumoniae isolate from Colombia. Antimicrob Agents Chemother (2011) 0.85
Outbreak of multi-drug resistant Pseudomonas aeruginosa bloodstream infection in the haematology unit of a South African Academic Hospital. PLoS One (2013) 0.79
Clonal Dissemination of Pseudomonas aeruginosa Sequence Type 235 Isolates Carrying blaIMP-6 and Emergence of blaGES-24 and blaIMP-10 on Novel Genomic Islands PAGI-15 and -16 in South Korea. Antimicrob Agents Chemother (2016) 0.79
Time Effectiveness of Ultraviolet C Light (UVC) Emitted by Light Emitting Diodes (LEDs) in Reducing Stethoscope Contamination. Int J Environ Res Public Health (2016) 0.78
The correlation between the presence of quorum sensing, toxin-antitoxin system genes and MIC values with ability of biofilm formation in clinical isolates of Pseudomonas aeruginosa. Iran J Microbiol (2014) 0.78
Prevalence and Clonal Dissemination of Metallo-Beta-Lactamase-Producing Pseudomonas aeruginosa in Kermanshah. Jundishapur J Microbiol (2015) 0.78
Reverse engineering antibiotic sensitivity in a multidrug-resistant Pseudomonas aeruginosa isolate. Antimicrob Agents Chemother (2006) 0.77
Emerging Carbapenem-Resistant Pseudomonas aeruginosa Isolates Carrying blaIMP Among Burn Patients in Isfahan, Iran. Arch Trauma Res (2016) 0.75
Role of Imipenem-resistant metallo-beta-lactamase positive pseudomonas aeruginosa carriers in nosocomial infections. J Nat Sci Biol Med (2013) 0.75
Molecular detection of metallo-β-lactamase gene blaVIM-1 in imipenem-resistant Pseudomonas aeruginosa strains isolated from hospitalized patients in the hospitals of Isfahan. Adv Biomed Res (2015) 0.75
Prevalence of Acquired Carbapenemase Genes in Klebsiella Pneumoniae by Multiplex PCR in Isfahan. Adv Biomed Res (2017) 0.75
Separation of large DNA molecules by contour-clamped homogeneous electric fields. Science (1986) 21.33
Determination of minimum inhibitory concentrations. J Antimicrob Chemother (2001) 10.33
Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect (2002) 8.93
Appearance of IMP-1 metallo-beta-lactamase in Europe. Lancet (1999) 5.41
Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother (1996) 5.36
Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother (2002) 4.80
Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother (2001) 4.72
Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol (2000) 4.67
Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol (2002) 4.15
bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother (2002) 4.01
Carbapenemases: a problem in waiting? Curr Opin Microbiol (2000) 3.98
Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother (1998) 3.57
Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7). Antimicrob Agents Chemother (2002) 2.97
Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis (2001) 2.86
Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase. Clin Infect Dis (2000) 2.61
Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. J Antimicrob Chemother (2003) 2.59
Carbapenem-hydrolysing VIM-2 metallo- beta-lactamase in Pseudomonas aeruginosa from Greece. J Antimicrob Chemother (2000) 2.29
Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4. J Antimicrob Chemother (2003) 1.97
Epidemiological typing of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis (1988) 1.89
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother (2001) 1.81
Genetic characterization of a novel metallo-beta-lactamase gene, blaIMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. J Antimicrob Chemother (2003) 1.74
BSAC standardized disc susceptibility testing method (version 3). J Antimicrob Chemother (2004) 1.73
Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. Clin Infect Dis (2003) 1.70
Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother (2002) 1.69
Carbapenemase-producing Pseudomonas aeruginosa in UK. Lancet (1998) 1.57
Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol (1998) 1.52
Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. Diagn Microbiol Infect Dis (2003) 1.41
IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. J Antimicrob Chemother (2002) 1.39
Resistance mechanisms of multiresistant serotype 012 Pseudomonas aeruginosa isolated in Europe. J Antimicrob Chemother (1990) 1.26
The global impact of drug resistance. Clin Infect Dis (2003) 1.13
Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis (1996) 1.12
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. J Antimicrob Chemother (2002) 1.05
Epidemiologically related and unrelated strains of Pseudomonas aeruginosa serotype O12 cannot be distinguished by phenotypic and genotypic typing. J Hosp Infect (1997) 1.02
Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother (2002) 0.83
Antibiotic resistance and molecular typing of Pseudomonas aeruginosa: focus on imipenem. Braz J Infect Dis (2002) 0.79
Molecular analysis of cellulose biosynthesis in Arabidopsis. Science (1998) 7.51
Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet (2001) 6.37
Assessment of resolution and intercenter reproducibility of results of genotyping Staphylococcus aureus by pulsed-field gel electrophoresis of SmaI macrorestriction fragments: a multicenter study. J Clin Microbiol (1998) 5.38
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother (1994) 4.87
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect (2012) 4.68
Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol (2000) 4.67
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrob Agents Chemother (1994) 4.43
Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2001) 4.15
Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A (1987) 4.04
Carbapenemases: a problem in waiting? Curr Opin Microbiol (2000) 3.98
High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect (1989) 3.95
Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev (1990) 3.82
IMP-4, a novel metallo-beta-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob Agents Chemother (2001) 3.80
Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother (2004) 3.69
Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect (2012) 3.58
Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol (1996) 3.52
Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother (2001) 3.51
Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother (1994) 3.34
Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob Agents Chemother (1990) 3.32
Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill (2010) 3.22
Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis. J Thromb Haemost (2014) 3.12
Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ (2000) 3.10
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother (1993) 3.09
Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii. Clin Microbiol Infect (2007) 3.00
Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother (1998) 2.94
Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae. Proc Natl Acad Sci U S A (1990) 2.82
Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill (2008) 2.78
Detection of the mec-A gene and phenotypic detection of resistance in Staphylococcus aureus isolates with borderline or low-level methicillinresistance. J Antimicrob Chemother (1996) 2.77
OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 2.77
A sensitive and specific phenotypic assay for detection of metallo-β-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clin Microbiol Infect (2011) 2.74
Contributions of dangling end stacking and terminal base-pair formation to the stabilities of XGGCCp, XCCGGp, XGGCCYp, and XCCGGYp helixes. Biochemistry (1985) 2.70
Carbapenem-hydrolysing IMP-1 beta-lactamase in Klebsiella pneumoniae from Singapore. Lancet (1999) 2.68
Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill (2013) 2.63
Vaporizer overfilling. Can J Anaesth (1993) 2.61
Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol (1995) 2.59
Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. J Antimicrob Chemother (1991) 2.59
Epidemiological typing of klebsiellae with extended-spectrum beta-lactamases from European intensive care units. J Antimicrob Chemother (1998) 2.51
Characterization of the plasmid mediated beta-lactamase BIL-1. J Antimicrob Chemother (1992) 2.48
Complexity and diversity of Klebsiella pneumoniae strains with extended-spectrum beta-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa. Antimicrob Agents Chemother (2001) 2.47
Resistance to extended-spectrum cephalosporins, caused by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, Turkey. J Med Microbiol (1995) 2.46
Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother (2011) 2.46
Correlation of typing methods for Acinetobacter isolates from hospital outbreaks. J Clin Microbiol (1993) 2.38
Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. J Infect Dis (1987) 2.37
Stability of XGCGCp, GCGCYp, and XGCGCYp helixes: an empirical estimate of the energetics of hydrogen bonds in nucleic acids. Biochemistry (1986) 2.32
Enterococcus faecium with high-level resistance to gentamicin. Lancet (1991) 2.28
OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain. Antimicrob Agents Chemother (1997) 2.28
Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet (1991) 2.27
Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother (2000) 2.27
Transferable production of PER-1 beta-lactamase in Pseudomonas aeruginosa. J Antimicrob Chemother (1995) 2.26
Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol (1983) 2.13
Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom. J Antimicrob Chemother (2006) 2.12
Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J Clin Microbiol (1993) 2.12
Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis (1990) 2.11
Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother (2000) 2.07
Comparison of ribotyping with conventional methods for the type identification of Enterobacter cloacae. J Clin Microbiol (1991) 2.06
Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07. J Antimicrob Chemother (2012) 2.04
Survey of the prevalence of beta-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother (1992) 2.00
Prehospital advanced life support: benefits in trauma. J Trauma (1984) 2.00
Do you relish interesting times? Call for applicants for the 2001 CMAJ Editorial Fellowship. CMAJ (2000) 1.93
Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother (2010) 1.83
In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases. J Antimicrob Chemother (1981) 1.78
Acinetobacter spp. isolates with reduced susceptibilities to carbapenems in a UK burns unit. J Antimicrob Chemother (1998) 1.77
A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England. J Hosp Infect (2004) 1.74
HTLV-1 infection in tropical spastic paraparesis: lymphocyte culture and serologic response. AIDS Res Hum Retroviruses (1988) 1.74
Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J Antimicrob Chemother (2005) 1.73
DNA banding pattern polymorphism in vancomycin-resistant Enterococcus faecium and criteria for defining strains. J Clin Microbiol (1999) 1.71
Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina. J Antimicrob Chemother (1999) 1.70
Carbapenemases of Chryseobacterium (Flavobacterium) meningosepticum: distribution of blaB and characterization of a novel metallo-beta-lactamase gene, blaB3, in the type strain, NCTC 10016. Antimicrob Agents Chemother (2000) 1.68
The primary care physician and Alzheimer's disease: an international position paper. J Nutr Health Aging (2010) 1.68
Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. J Antimicrob Chemother (1990) 1.67
Post-mortem radiology--a new sub-speciality? Clin Radiol (2008) 1.67
Characterization of an LysR family protein, SmeR from Serratia marcescens S6, its effect on expression of the carbapenem-hydrolyzing beta-lactamase Sme-1, and comparison of this regulator with other beta-lactamase regulators. Antimicrob Agents Chemother (1995) 1.67
Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J Clin Microbiol (2002) 1.67
Antimicrobial resistance amongst enterococci isolated in the United Kingdom: a reference laboratory perspective. J Antimicrob Chemother (1993) 1.65
Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother (2006) 1.64
Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin Microbiol Infect (2009) 1.63
Are SHV beta-lactamases universal in Klebsiella pneumoniae? Antimicrob Agents Chemother (2000) 1.61
Molecular analysis of diverse elements mediating VanA glycopeptide resistance in enterococci. J Antimicrob Chemother (1998) 1.61
Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in Western Europe. Antimicrob Agents Chemother (2000) 1.61
Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol (1996) 1.60
Interactions of meropenem with class I chromosomal beta-lactamases. J Antimicrob Chemother (1989) 1.60
Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother (2005) 1.60
The MRC and informed consent. Br Med J (Clin Res Ed) (1986) 1.59
Carbapenemase-producing Pseudomonas aeruginosa in UK. Lancet (1998) 1.57